Salk researchers develop novel brain cancer glioblastoma mouse model. – Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma-the most common and deadly brain cancer in humans-that closely resembles the development and progression of human brain tumors that arise naturally.
MRSA pre-screening effective in reducing otolaryngic surgical infection rates, revealed by researchers in Otolaryngology ? Head and Neck Surgery. – Pre-operative screening of patients for methicillin-resistant staphylococcus aureus (MRSA) may be an effective way to reduce infection rates following otolaryngic surgeries, according to new research published in the January 2009 issue of Otolaryngology ? Head and Neck Surgery.
Breathing life into injured lungs: World-first technique will expand lung donor organ pool – For the first time in the world, transplant surgeons at Toronto General Hospital, University Health Network used a new technique to repair an injured donor lung that was unsuitable for transplant, and then successfully transplanted it into a patient.
Protein identified as TIM 3 that turns off HIV-fighting T cells in HIV positive patients sufferring from AIDS. – In HIV-infected patients the body’s immune system is unable to fight off the virus. A new study to be published online on November 10th in the Journal of Experimental Medicine shows that T cells in HIV-infected individuals express a protein called TIM-3, which inactivates their virus killing capacity.
Study suggests HIV infected patients should start highly active antiretroviral therapy (HAART) sooner. – Under current treatment guidelines, highly active antiretroviral therapy (HAART) should be considered for HIV-infected patients when their CD4+ T-cell counts fall below 350 cells per cubic millimeter (mm3).
Living Cell Technologies receives New Zealand’s Health Minister?s approval to start leading edge live cell therapy clinical trial in New Zealand for Diabetes patients. – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell?, LCT’s lead product candidate for the treatment of insulin dependent (Type 1) diabetes.
Research indicates drug alemtuzumab not only stops the Multiple sclerosis disease from advancing but may also restore lost function in many Multiple sclerosis patients. – A drug which was developed in Cambridge and initially designed to treat a form of leukaemia has also proven effective against combating the debilitating neurological disease multiple sclerosis (MS).
US FDA Approves Updated Labeling for Psoriasis Drug Raptiva by Genentech; Safety concerns drove labeling changes. – The U.S. Food and Drug Administration announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab).
Allergic rhinitis or hay fever or seasonal allergy can be treated with self adjusted dosing of intranasal corticosteroid triamcinolone acetonide. – Hay fever, the often seasonal allergy that affects between 10 and 20 percent of the American population, is best controlled through a course of patient-adjusted dosing, according to new research published in the September 2008 edition of Otolaryngology ? Head and Neck Surgery.
Friendly? bacteria in stomach protect against type 1 diabetes, Yale researchers find. – In a dramatic illustration of the potential for microbes to prevent disease, researchers at Yale University and the University of Chicago showed that mice exposed to common stomach bacteria were protected against the development of Type I diabetes.
